Sleep Apnea Telemedicine Platform Secures $6.8 Million in Funding Sleep Review Staff

The funding will be used to propel AI-driven platform enhancements, expand coverage, and improve care coordination.

Summary: Ognomy Inc, a telemedicine platform for sleep apnea diagnosis and treatment, has successfully closed its Series Seed Preferred financing round, raising over $6.8 million since its inception. Led by Impellent Ventures and supported by a strategic partner in the sleep medicine industry, the funding will be used to enhance the platform with AI-driven automation, expand coverage to all 50 states by the end of 2024, and improve care coordination for sleep apnea patients. The company has already served over 11,000 patients.

Key Takeaways:

1. Funding Achieved: Ognomy has raised over $6.8 million since its inception and plans to use the funds to enhance its platform with AI-driven capabilities and expand its telemedicine services nationwide.
2. Rapid Growth and Expansion: Ognomy currently operates in 43 states and plans to achieve full nationwide coverage by the end of 2024.
3. AI Integration for Better Care: The newly secured funds will be directed toward integrating AI-driven automation and improving information exchange on Ognomy’s platform, aiming to streamline the patient journey and improve care coordination for those with from sleep apnea.

Ognomy Inc, a sleep apnea telemedicine platform, announced it has successfully closed its Series Seed Preferred financing round, now having raised over $6.8 million since inception. 

This round was led by Impellent Ventures, with backing from a leading strategic partner in the sleep medicine industry. The company also announced it surpassed 11,000 patients served.

Ognomy’s patients can see a clinician within days and embark on a personalized treatment plan shortly thereafter. Ognomy has coverage in 43 states and will have full nationwide coverage by the end of 2024. 

“Sleep apnea is one of the most chronically underdiagnosed and undertreated issues in America, with dire consequences. Ognomy has consistently demonstrated its ability to innovate for this critical need in the healthcare industry,” says David Brown, a partner at Impellent Ventures, in a release. “We are excited to support Ognomy as their platform quickly becomes the preeminent way to ensure long-term patient health. Their commitment to improving sleep health through technology has allowed for rapid growth for the company and makes Ognomy well-positioned to have a significant impact on the lives of those suffering from sleep apnea.”

Plans for Funding

The newly raised funds will be used to integrate additional artificial intelligence (AI)-driven automation and information exchange into Ognomy’s platform. These advancements aim to further streamline the patient journey, from initial diagnosis to ongoing management to care coordination, to make the process faster, more efficient, and more accessible.

“We are thrilled to have the backing of Impellent Ventures and our new strategic partner,” says Daniel Rifkin, CEO of Ognomy, in a release. “This funding will allow us to accelerate our mission of providing accessible, high-quality care for sleep apnea patients across the country. With AI-driven automation and a fully integrated platform, we are poised to revolutionize the way sleep apnea is diagnosed and treated.”

ID 133918198 © Jae Young Ju | Dreamstime.com